NRG-GY018 at ASCO 2026: Pembrolizumab Plus Chemotherapy Sustains Overall Survival Benefit in Advanced Endometrial Cancer
oncodaily - The NRG-GY018 trial returned to the ASCO 2026 stage with the question that matters more than any progression endpoint: do patients actually live longer? Presented by Ramez N. Eskander, MD […]
AI Summary: Updated results from the NRG‑GY018 trial show adding pembrolizumab to chemotherapy sustains an overall survival benefit in advanced endometrial cancer. The follow‑up confirms the durability of immunotherapy’s impact and supports integrating checkpoint inhibitors into standard regimens for eligible patients, potentially changing practice for a cancer type that’s long hungered for better systemic options.
Related Stories
Merck and Moderna report positive phase‑3 melanoma vaccine results / 17 days
Belzutifan plus lenvatinib outperforms cabozantinib in advanced RCC / 18 days
First patient enrolled in AACR-ADOPT-GEA gastroesophageal cancer trial / 28 days
Phase 1 trial shows cevostamab activity in relapsed multiple myeloma / 6 wks
EMERALD‑3 tests tremelimumab/durvalumab combos for embolisation‑eligible HCC / 2 months
Long‑term Botensilimab+Balstilimab data show durable responses in MSS CRC / 2 months
Zanidatamab improves PFS over trastuzumab in HER2 GEA / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Weight Loss, Genetics, Long COVID, Diabetes and look for the RSS link.
StackHealth Time Machine